BI Asset Management Fondsmaeglerselskab A S Buys 9,265 Shares of Insulet Corporation $PODD

BI Asset Management Fondsmaeglerselskab A S increased its position in shares of Insulet Corporation (NASDAQ:PODD) by 258.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,856 shares of the medical instruments supplier’s stock after buying an additional 9,265 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Insulet were worth $3,969,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Savant Capital LLC lifted its holdings in shares of Insulet by 12.5% during the 3rd quarter. Savant Capital LLC now owns 6,996 shares of the medical instruments supplier’s stock worth $2,160,000 after acquiring an additional 777 shares during the period. Machina Capital S.A.S. bought a new position in Insulet during the third quarter worth about $2,778,000. J.W. Cole Advisors Inc. boosted its holdings in Insulet by 26.8% during the third quarter. J.W. Cole Advisors Inc. now owns 1,059 shares of the medical instruments supplier’s stock valued at $327,000 after purchasing an additional 224 shares in the last quarter. Envestnet Asset Management Inc. boosted its holdings in Insulet by 1.9% during the third quarter. Envestnet Asset Management Inc. now owns 136,166 shares of the medical instruments supplier’s stock valued at $42,039,000 after purchasing an additional 2,514 shares in the last quarter. Finally, Allianz Asset Management GmbH grew its stake in shares of Insulet by 27.2% in the 3rd quarter. Allianz Asset Management GmbH now owns 334,426 shares of the medical instruments supplier’s stock valued at $103,247,000 after purchasing an additional 71,548 shares during the period.

Insulet Trading Down 0.5%

NASDAQ PODD opened at $241.93 on Friday. Insulet Corporation has a 12 month low of $230.05 and a 12 month high of $354.88. The stock has a 50-day simple moving average of $283.49 and a 200 day simple moving average of $307.72. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $17.02 billion, a PE ratio of 70.12, a P/E/G ratio of 1.37 and a beta of 1.41.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.13 by $0.11. The business had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The firm’s revenue was up 29.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.08 EPS. Research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Wells Fargo & Company increased their price objective on Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Jefferies Financial Group upped their target price on shares of Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Barclays lifted their price target on shares of Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a report on Wednesday, November 5th. Truist Financial decreased their price objective on shares of Insulet from $412.00 to $390.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Finally, Wolfe Research raised their price objective on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Twenty investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and an average price target of $374.10.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.